PD-L1 expression was associated with the non-GCB subtype and correlated with improved PFS and survival, suggesting that PD-L1 could serve as a biomarker to identify DLBCL patients who might benefit from this first-line treatment strategy. Here, CD274 is linked to diffuse large B-cell lymphoma.